2005
DOI: 10.1158/0008-5472.can-05-0882
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Modulation of aberrant cell cycle regulation is a potential therapeutic strategy applicable to a wide range of tumor types. JNJ-7706621 is a novel cell cycle inhibitor that showed potent inhibition of several cyclin-dependent kinases (CDK) and Aurora kinases and selectively blocked proliferation of tumor cells of various origins but was about 10-fold less effective at inhibiting normal human cell growth in vitro. In human cancer cells, treatment with JNJ-7706621 inhibited cell growth independent of p53, retino… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
75
0

Year Published

2006
2006
2020
2020

Publication Types

Select...
7
2

Relationship

1
8

Authors

Journals

citations
Cited by 111 publications
(78 citation statements)
references
References 45 publications
3
75
0
Order By: Relevance
“…Another inhibitor with a very broad inhibition spectrum is Triazolodiamine 1. Close analogues of this inhibitor have been developed as dual Cdk/Aurora inhibitors and are now in clinical trials (19). The identified lack of selectivity by Triazolodiamine 1 raises the possibility that its derivatives also target more kinases in vivo than was originally designed for.…”
Section: Resultsmentioning
confidence: 99%
“…Another inhibitor with a very broad inhibition spectrum is Triazolodiamine 1. Close analogues of this inhibitor have been developed as dual Cdk/Aurora inhibitors and are now in clinical trials (19). The identified lack of selectivity by Triazolodiamine 1 raises the possibility that its derivatives also target more kinases in vivo than was originally designed for.…”
Section: Resultsmentioning
confidence: 99%
“…Cell Cycle Analysis Cells were stained with propidium iodide for the analysis of nuclear DNA content as previously described (1).…”
Section: Methodsmentioning
confidence: 99%
“…This compound delays the progression of cancer cells through G 1 phase and arrests the cell cycle in G 2 -M phase. It is cytotoxic to a wide range of tumor cell types, and produces antitumor activity in human tumor xenograft models (1). This compound is one of the first promising antineoplastic agents being developed as a dual CDK/Aurora kinase inhibitor.…”
Section: Introductionmentioning
confidence: 99%
“…HumanTumor Xenograft Studies The effects of recombinant epoetins (epoetin a, darbepoetin a, and epoetin h) on paclitaxel therapy in xenograft models were assessed using methods described elsewhere (36). Briefly, female nu/nu mice were implanted orthotopically in the mammary fat pad with MCF-7 or MDA-MB-231 cells (10 7 or 5 Â 10 6 , respectively) from culture.…”
Section: Proliferation Assaysmentioning
confidence: 99%